Population
In vitro human, dog, and rat plasma; in vivo rats and dogs, including a rat model of FeCl2-induced carotid…
Comparison
RPR120844 administered via intravenous bolus… vs Vehicle (in the rat thrombosis model)
Design
Preclinical
Follow-up
60 min (maximal observation time in thrombosis model)
Authors
Loading...
Supports oral factor Xa inhibition in arterial thrombosis models; hypothesis-generating and requires clinical validation.
RPR120844 is a potent, selective, and orally active factor Xa inhibitor that demonstrates antithrombotic efficacy in a preclinical model of arterial thrombosis.
Leadley et al. (1999) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: